There are promising results indicating that treatment with the recombinant protein improves host defense in the immunosuppressive phenotype of sepsis, but due to the dose-dependent ambivalent physiological and pathophysiological effects of IFNγ much work is still necessary in particular to establish which subgroups might be harmed. This evidence concerns the gene IFNG and Sepsis.